2015 ICD-9-CM Diagnosis Code 199.1. Other malignant neoplasm without specification of site. ICD-9-CM 199.1 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 199.1 should only be used for claims with a date of service on or before September 30, 2015.
ICD-9 Code 170.1 Malignant neoplasm of mandible. ICD-9 Index; Chapter: 140–239; Section: 170-176; Block: 170 Malignant neoplasm of bone and articular cartilage; 170.1 - Malignant neo …
Short description: Malignant neoplasm NOS. ICD-9-CM 199.1 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 199.1 should only be used for claims with a date of service on or before September 30, 2015.
20 rows · There are often multiple ICD-10 codes for a given ICD-9 code, so use caution! Contents. 1 ...
170.1 is a legacy non-billable code used to specify a medical diagnosis of malignant neoplasm of mandible. This code was replaced on September 30, 2015 by its ICD-10 equivalent.
References found for the code 170.1 in the Index of Diseases and Injuries:
Cancer that starts in a bone is uncommon. Cancer that has spread to the bone from another part of the body is more common.
General Equivalence Map Definitions#N#The ICD-9 and ICD-10 GEMs are used to facilitate linking between the diagnosis codes in ICD-9-CM and the new ICD-10-CM code set. The GEMs are the raw material from which providers, health information vendors and payers can derive specific applied mappings to meet their needs.
195.2 Abdominal cavity#N#173.5 Abdominal wall (skin)#N#154.3 Anus (anal)#N#156.9 Biliary tract (cholangiocarcinoma), unspecified site#N#188.9 Bladder, unspecified site#N#233.7 Bladder, in situ#N#191.9 Brain, unspecified site#N#174.9 Breast, female, unspecified site#N#233.0 Breast, in situ (DCIS)#N#175.9 Breast, male, unspecified site#N#162.9 Bronchus, unspecified site#N#180.9 Cervix (cervival), unspecified site#N#233.1 Cervix uteri, in situ#N#170.9 Chondrosarcoma#N#153.9 Colon (colorectal), unspecified site#N#182.0 Endometrium (endometrial)#N#150.9 Esophagus (esophageal), unspecified site#N#170.9 Ewing's sarcoma#N#159.9 Gastrointestinal tract, unspecified site#N#184.9 Genital, female, unspecified site#N#187.9 Genital, male, unspecified site#N#153.9 Intestine (bowel), large, unspecified site#N#152.9 Intestine (bowel), small, unspecified site#N#176.9 Kaposi's Sarcoma, unspecified site#N#189.0 Kidney (renal)#N#155.0 Liver (hepatocellular), primary#N#155.2 Liver, not specified as primary or secondary#N#162.9 Lung (adenocarcinoma/squamous cell carcinoma), unspecified site#N#209.36 Merkel cell carcinoma#N#145.9 Mouth, unspecified site#N#147.9 Nasopharynx, unspecified site#N#170.9 Osteosarcoma#N#183.0 Ovary (ovarian)#N#157.9 Pancreas (pancreatic), unspecified part#N#163.8 Pleura/contiguous sites#N#185 Prostate#N#233.4 Prostate, in situ#N#154.1 Rectum#N#158.0 Retroperitoneum#N#171.9 Rhabdosarcoma#N#142.9 Salivary gland, unspecified site#N#171.9 Sarcoma, connective or soft tissue#N#172.9 Skin, melanoma, unspecified site#N#173.9 Skin, unspecified malignancy, unspecified site#N#151.9 Stomach, unspecified site#N#186.9 Testis (testicular), unspecified site#N#195.1 Thorax#N#193 Thyroid#N#141.9 Tongue, unspecified site#N#199.1 Unknown primary#N#179 Uterus (uterine), unspecified site.
207.00 Acute erythremia & erythroleukemia#N#207.00 Acute lymphoid leukemia (ALL)#N#206.00 Acute monocytic leukemia#N#205.00 Acyte myeloid leukemia (AML)#N#208.00 Acute leukemia, unspecified#N#277.30 E85.9 Amyloidosis#N#208.10 Chronic leukemia, unspecified#N#204.10 Chronic lymphoid leukemia (CLL)#N#206.10 Chronic monocytic leukemia#N#205.10 Chronic myeloid leukemia (CML)#N#202.40 Hairy cell leukemia#N#207.20 Megakaryocytic leukemia#N#273.1 D47.2 Monoclonal gammopathy of undetermined significance (MGUS)#N#203.00 C90.0 [0-2] Multiple myeloma (MM)#N#203.10 C90.1 [0-2] Plasma cell leukemia.
284.11 Antineoplastic chemotherapy induced pancytopenia#N#285.3 Antineoplastic chemotherapy induced anemia#N#995.29 Complication of chemotherapy#N#999.81 Extravasation of vesicant chemotherapy#N#V07.39 Need for other prophylactic chemotherapy#N#V58.11 Encounter for antineoplastic chemotherapy#N#V66.2 Convalescence following chemotherapy#N#V67.2 Follow-up examination following chemotherapy#N#V87.41 Personal history of antineoplastic chemotherapy.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm. Morphology [Histology] Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, ...
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm. Morphology [Histology] Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, ...
Thyroid cancer metastatic to bone. Clinical Information. Cancer that has spread from the original (primary) tumor to the bone. The spread of a malignant neoplasm from a primary site to the skeletal system. The majority of metastatic neoplasms to the bone are carcinomas.
It tends to occur in the long bones (particularly distal femur, proximal tibia, and proximal humerus), but can occur in any bone. The lungs are the most common site of metastasis.
Treatment may include chemotherapy, radiation, surgery, bone grafting, limb-amputation, and limb-saving (salvage) surgery.
It tends to occur in the long bones (particularly distal femur, proximal tibia, and proximal humerus), but can occur in any bone. The lungs are the most common site of metastasis. Kidneys, adrenal gland, brain, and heart can also be sites of metastasis.
The lungs are the most common site of metastasis. Kidneys, adrenal gland, brain, and heart can also be sites of metastasis. DIAGNOSTIC TESTING, PHYSICAL FINDINGS, AND ICD-9-CM/ICD-10-CM CODING. Diagnostic testing: Diagnostic testing for osteosarcoma includes: Radionuclide bone scans.
• 170 Malignant neoplasm of bone and articular cartilage
• 171 Malignant neoplasm of connective and other soft tissue
• 172 Malignant melanoma of skin
• 173 Other malignant neoplasm of skin
• 140 Malignant neoplasm of lip
• 141 Malignant neoplasm of tongue
• 142 Malignant neoplasm of major salivary glands
• 143 Malignant neoplasm of gum
• 150 Malignant neoplasm of esophagus
• 151 Malignant neoplasm of stomach
• 152 Malignant neoplasm of small intestine, including duodenum
• 153 Malignant neoplasm colon
• 160 Malignant neoplasm of nasal cavities, middle ear, and accessory sinuses
• 161 Malignant neoplasm of larynx
• 162 Malignant neoplasm of trachea, bronchus, and lung
• 163 Malignant neoplasm of pleura
• 176 Kaposi's sarcoma
• 176 Kaposi's sarcoma
• 179 Malignant neoplasm of uterus, part unspecified
• 180 Malignant neoplasm of cervix uteri
• 181 Malignant neoplasm of placenta
• 182 Malignant neoplasm of body of uterus
• 179 Malignant neoplasm of uterus, part unspecified
• 180 Malignant neoplasm of cervix uteri
• 181 Malignant neoplasm of placenta
• 182 Malignant neoplasm of body of uterus
• 190 Malignant neoplasm of eye
• 191 Malignant neoplasm of brain
• 192 Malignant neoplasm of other and unspecified parts of nervous system
• 193 Malignant neoplasm of thyroid gland